EPAS1 and hepatocellular carcinoma: In hepatocellular carcinoma, long-term treatment with sorafenib deprives tumors of oxygen over time, which can contribute to the proliferation of cancer cells that can tolerate low oxygen levels, which in part may explain the clinical observation that increased expression of HIF-1α and HIF-2α in HCC patients are markers of poor prognosis [123].